U-Neuron Biomedical Inc
TTPEX:697357.90
TWD
-0.80
(-1.36%)
ISIN
TW0006973001
Return %
Stock
S&P 500
1Y
35.76
14.39
3Y
53.55
81.42
5Y
- -
68.62
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Hsiao Min Huang
- Full Time Employees
- 30
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- No. 99, Section 1 New Taipei Taiwan 22102
- IPO Date
- Jul 20, 2023
- Website
- u-neuron.com
- Similar Companies
- Business
- U-Neuron Biomedical Inc (6973.TWO) develops and manufactures advanced neurostimulation devices and related medical technologies for treating neurological disorders. The company offers implantable deep brain stimulation (DBS) systems, including the UniStim DBS device with programmable leads and rechargeable pulse generators; non-invasive focused ultrasound neuromodulation platforms; and associated software for therapy programming and patient monitoring. These products target conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy, serving healthcare providers and patients primarily in Asia and expanding into global markets. Founded in 2016 and headquartered in Hsinchu, Taiwan, U-Neuron operates in the medtech industry with a focus on neuromodulation segments, including hardware manufacturing, clinical trials support, and regulatory compliance services for neurodevices. Its target customers include hospitals, neurology clinics, and research institutions seeking precise, minimally invasive brain stimulation solutions. In the last two years, U-Neuron listed on the Taipei Exchange (TWO) in 2023, marking a key capital markets milestone; completed CE Mark certification for its UniStim DBS system in Europe in 2024, enabling market entry; and announced strategic partnerships with Asian distributors for commercial rollout. The company also raised funds through a 2024 private placement to support R&D expansion and initiated Phase III clinical trials for new epilepsy indications. These developments position U-Neuron for accelerated growth in the competitive neuromodulation sector.